Last reviewed · How we verify
Isoptin (VERAPAMIL)
Isoptin (Verapamil) is a calcium channel blocker, a small molecule modality developed by Pfizer and currently owned by Mt. Adams. It targets the voltage-dependent L-type calcium channel subunit alpha-1C, reducing calcium influx into cardiac and smooth muscle cells. Approved indications include acute coronary syndrome, angina pectoris, atrial fibrillation, and paroxysmal supraventricular tachycardia. Isoptin is off-patent, with 37 generic manufacturers, and has a half-life of 2.8 hours and bioavailability of 22%. Key safety considerations include potential interactions with other medications and effects on heart rate and blood pressure.
At a glance
| Generic name | VERAPAMIL |
|---|---|
| Sponsor | Mt Adams |
| Drug class | Calcium Channel Blocker |
| Target | Voltage-dependent L-type calcium channel subunit alpha-1C |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Acute coronary syndrome
- Angina pectoris
- Atrial fibrillation
- Cardioversion of Atrial Fibrillation
- Hypertensive disorder
- Paroxysmal supraventricular tachycardia
- Prevention of Paroxysmal Supraventricular Tachycardia
- Prinzmetal angina
Common side effects
- Constipation
- Dyspnea
- Dizziness
- Bradycardia (HR <50/min)
- Nausea
- AV block total (1, 2, 3)
- Hypotension
- Headache
- Rash
- Edema
- Flushing
- Fatigue
Drug interactions
- P-glycoprotein Substrates
- alfentanil
- buspirone
- ketoconazole
- quinidine
- tacrolimus
- telaprevir
Key clinical trials
- Safety and Efficacy of HB-1 for PTSD: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study (PHASE2)
- SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation (PHASE4)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1,PHASE2)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Comparison of Intralesional Triamcinolone Acetonide Treatment With Intralesional Verapamil Hydrochloride in Keloids (NA)
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (PHASE4)
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Rate Control in Patients With Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |